For UA/NSTEMI patients in whom CABG is selected as a postangiography management strategy, the instructions noted below should be followed. 2011 recommendation remains current. a. Continue aspirin.84 90 (Level of Evidence: A) b. See Class I, #3, in this section. c. Discontinue IV GP IIb/IIIa inhibitor (eptifibatide or tirofiban) 4 hours before CABG.84,88,91 (Level of Evidence: B) d. Anticoagulant therapy should be managed as follows: 1. Continue UFH.80,92 94 (Level of Evidence: B) 2. Discontinue enoxaparin 12 to 24 hours before CABG and dose with UFH per institutional practice.80,92 94 (Level of Evidence: B) 3. Discontinue fondaparinux 24 hours before CABG and dose with UFH per institutional practice.95,96 (Level of Evidence: B) 4. Discontinue bivalirudin 3 hours before CABG and dose with UFH per institutional practice.97,98 (Level of Evidence: B) 3. In patients taking a P2Y12 receptor inhibitor in whom CABG is planned and can be delayed, it is recommended that the drug be discontinued to allow for dissipation of the antiplatelet effect13 (Level of Evidence: B). The period of withdrawal should be at least 5 days in patients receiving clopidogrel13,45,99 (Level of Evidence: B) or ticagrelor*12 (Level of Evidence: C) and at least 7 days in patients receiving prasugrel 8 (Level of Evidence: C) unless the need for revascularization and/or the net benefit of the P2Y12 receptor inhibitor therapy outweighs the potential risks of excess bleeding.100 (Level of Evidence: C) modified (included ticagrelor). 4. For UA/NSTEMI patients in whom PCI has been selected as a postangiography management strategy, the instructions noted below should be followed: modified ( thienopyridine replaced with P2Y12 receptor inhibitor ). a. 